{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:39Z","timestamp":1761100539138},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,2,11]],"date-time":"2002-02-11T00:00:00Z","timestamp":1013385600000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p><jats:bold>Summary.<\/jats:bold> Although outcome in multiple myeloma (MM) patients has improved significantly with the introduction of autotransplants (AT), the curability of this approach remained to be demonstrated. Therefore, we analysed outcome and prognostic factors using a logistic regression model in 515 consecutive newly diagnosed and previously treated patients intended to receive melphalan\u2010based tandem transplants with follow up of \u2265 5\u2003years. One quarter ofpatients had event\u2010free survivals (EFS) \u2265\u200a5\u2003years with no further relapses seen after 7\u2003years (46 patients on plateau). On multivariate analysis, factors associated with EFS \u2265\u200a5\u2003years were absence of chromosome 11 and 13 abnormalities (odds ratio: 6\u00b71), \u2264\u200a12\u2003months of preceding standard\u2010dose therapy (SDT) (OR: 2\u00b76) and \u03b2\u20102 microglobulin (B<jats:sub>2<\/jats:sub>M) level \u2264\u200a2\u00b75\u2003mg\/l at time of first AT (OR: 1\u00b77). Patients with only favourable variables (25%) had a 7\u2010year EFS in excess of 35%, compared with 15% and 10%, respectively, with one (43%) or two unfavourable variables (27%), and 0% for 5% of patients with three unfavourable variables (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001). Using a 1\u2010year landmark analysis to allow for guaranteed time and thereby excluding early treatment failures, attaining a complete remission (CR) had no significant effect on long\u2010term survival. Our data are consistent with cure in MM patients with a CR duration \u2265\u200a7\u2003years and re\u2010establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression \u2265\u200a7\u2003years.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2002.03231.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:41:35Z","timestamp":1047364895000},"page":"211-217","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Predicting long\u2010term (\u2265\u20035\u2003years) event\u2010free survival in multiple myeloma patients following planned tandem autotransplants"],"prefix":"10.1111","volume":"116","author":[{"given":"Guido","family":"Tricot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trey","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Spoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Desikan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Fassas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Badros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Anaissie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Toor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,2,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830330203"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.65"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_6_5_1","first-page":"714a","article-title":"Single versus double transplant in myeloma: a randomized trial of the \u2018inter groupe fran\u00e7ais du my\u00e9lome\u2019 (IFM)","volume":"94","author":"Attal M.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_6_1","first-page":"557a","article-title":"Single versus doubletransplantation in myeloma: a prospective randomized trial of the inter groupe francophone du myelome (IFM)","volume":"96","author":"Attal M.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.9.2326.2326"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.789"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.55.401k04_55_65"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case\u2010matched study from the European group for blood and marrow transplantation","volume":"88","author":"Bj\u00f6rkstrand B.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.208"},{"key":"e_1_2_6_13_1","first-page":"169a","article-title":"Intensive consolidationtherapy after tandem transplants further improves theoutcome of multiple myeloma (MM) patients","volume":"96","author":"Desikan R.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.4008"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1312"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701975"},{"key":"e_1_2_6_17_1","first-page":"520","article-title":"Evaluation of dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival","volume":"6","author":"Goasguen J.E.","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60015-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2234"},{"key":"e_1_2_6_20_1","first-page":"7","article-title":"Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study","volume":"95","author":"Lenhoff S.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701362"},{"key":"e_1_2_6_22_1","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N.","year":"1966","journal-title":"Cancer Chemotherapy Report"},{"key":"e_1_2_6_23_1","first-page":"419a","article-title":"High\u2010dose melphalan and auto transplantation in myeloma with renal impairment: a matched\u2010pair comparison with patients without renal failure","volume":"97","author":"Mehta J.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08901.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700917"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2122.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702640"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood.V87.2.746.bloodjournal872746","article-title":"Ig VH Gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance","volume":"87","author":"Sahota S.S.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_29_1","first-page":"548a","article-title":"Chromosome 13 deletion (del 13) using tri\u2010color FISH in multiple myeloma (MM) \u2013 lack of prognostic implications in patients (PTS) receiving total therapy","volume":"96","author":"Shaughnessy J.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.51"},{"key":"e_1_2_6_31_1","first-page":"153a","article-title":"In multiple myeloma, low but detectable intraclonal diversity suggests that malignant and non\u2010malignant clonal relatives co\u2010exist","volume":"96","author":"Taylor B.J.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_32_1","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis inmultiple myeloma is associated only with partial or completedeletions of chromosome 13 or abnormalities involving 11qand not wit other karyotype abnormalities","volume":"86","author":"Tricot G.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2659"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2002.03231.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2002.03231.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2002.03231.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:16:24Z","timestamp":1697415384000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2002.03231.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1046\/j.1365-2141.2002.03231.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03231.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"2002-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}